INDOCIN (indomethacin) by R-Pharm US is cyclooxygenase inhibitors [moa]. First approved in 1985.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
INDOCIN (indomethacin) is an oral nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain. It is used to treat a range of inflammatory and pain conditions, though specific indications are not detailed in current labeling. The drug has been on the market since 1985 and is now approaching loss of exclusivity.
As LOE approaches, the brand team is likely focused on cost management and retention strategy rather than expansion; team size may contract post-LOE.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Worked on INDOCIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on INDOCIN offers limited career growth opportunity given its approaching loss of exclusivity and lack of clinical pipeline activity. Roles on this product are primarily commercial and defensive, focused on managing market share erosion and cost rather than driving innovation or expansion.